ATAI Stock Intrinsic Value – Atai Life Sciences N.V. Stock Drops 2.06% Despite Analyst EPS Estimate Increase
May 25, 2023
Trending News ☀️
Atai Life Sciences ($NASDAQ:ATAI) N.V. is a biopharmaceutical company focused on developing and commercializing innovative therapies for mental health and neurological disorders. Despite analysts increasing their EPS estimates, Atai Life Sciences N.V. stock dropped 2.06%, closing the day at $1.90. It is unclear why investors are unimpressed by the analysts’ EPS estimates, but it could be due to a number of factors including a slowing of growth, or other macroeconomic factors such as higher inflation and weak consumer confidence. Despite this, many analysts continue to remain bullish on the stock and believe it has potential for future growth.
Earnings
ATAI LIFE SCIENCES N.V recently reported their financials for the first quarter of FY2023, ending March 31 2023. Despite an increase in the analyst estimate for earnings per share (EPS), their stock prices dropped 2.06%. The company reported total revenue of 0.04M USD and a net loss of 33.14M USD. This marks a stark decrease from the 19.88M USD in total revenue reported in the same quarter of the previous year.
Atai Life Sciences N.V has seen decreasing revenues over the last three years, from 19.88M USD to 0.04M USD in this latest quarter. Despite the analyst EPS estimate increase that did not appear to have any effect on the stock price, the company still struggled to make profits and reported a large net loss in the first quarter of FY2023.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ATAI. More…
| Total Revenues | Net Income | Net Margin |
| 0.27 | -148.65 | -57022.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ATAI. More…
| Operations | Investing | Financing |
| -101.59 | 143.91 | 20.86 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ATAI. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 280.72 | 40.08 | 1.43 |
Key Ratios Snapshot
Some of the financial key ratios for ATAI are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -53719.6% |
| FCF Margin | ROE | ROA |
| -38149.3% | -36.4% | -32.3% |
Analysis – ATAI Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of ATAI LIFE SCIENCES N.V.’s wellbeing. Our proprietary Valuation Line has concluded that the fair value of ATAI LIFE SCIENCES N.V share is around $1.8. At present, the stock is being traded at $1.9, which is a fair price overvalued by 7.3%. More…
Peers
The company’s lead product candidate, ATAI-002, is a proprietary, orally-active small molecule that is being developed for the treatment of depression. ATAI Life Sciences NV has a strategic partnership with Janssen Pharmaceuticals, Inc. for the development and commercialization of ATAI-002. The company’s competitors include Evofem Biosciences Inc, Soligenix Inc, and Aerovate Therapeutics Inc.
– Evofem Biosciences Inc ($NASDAQ:EVFM)
Soligenix is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to treat serious inflammatory conditions and other diseases of the gastrointestinal tract. The company’s lead product candidates are SGX301, an investigational new drug for the treatment of cutaneous T-cell lymphoma, and SGX942, an investigational new drug for the treatment of oral mucositis.
– Soligenix Inc ($NASDAQ:SNGX)
Aerovate Therapeutics Inc is a clinical stage biopharmaceutical company developing gene therapies for the treatment of rare, life-threatening diseases. The company’s most advanced product candidate is AERO-101, an adeno-associated virus (AAV) based gene therapy in development for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is a rare, inherited disease that can lead to liver damage and lung disease. There are currently no approved treatments for AATD.
Aerovate has a market cap of 513.41M as of 2022 and a return on equity of -15.06%. The company is developing gene therapies for the treatment of rare, life-threatening diseases.
Summary
Atai Life Sciences N.V. is a publicly traded biopharmaceutical company focused on neurological and psychiatric disorders. Analysts have been providing estimates for Atai Life Sciences N.V. in the form of consensus EPS estimates. As of the closing price of $1.90 on the day of the report, the stock is trading slightly above this consensus EPS estimate.
Since its listing, the stock has been volatile with wide fluctuations in price. Investors should conduct further research before investing in Atai Life Sciences N.V. as there are several risks associated with investing in the company such as the long-term success of their products, regulatory risks, and competition from other pharmaceutical companies.
